Skip to main content

Naomi Eichenbaum

Head of Investor Relations

Travere Therapeutics, Inc. (TVTX)

Equibles does not estimate personal net worth.

Get an email with a short summary when Travere Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get TVTX alerts

About Naomi Eichenbaum

Naomi Eichenbaum is recorded as Head of Investor Relations at Travere Therapeutics, Inc. (TVTX). Naomi Eichenbaum has spoken on 4 earnings calls across 1 company, most recently for Travere Therapeutics, Inc. on November 7, 2023. Travere Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Travere Therapeutics, Inc. includes Bradley Campbell (CEO and Board Member), Bradley L. Campbell (CEO and Board Member), Christopher Cline (CFO) and 7 others.

Naomi Eichenbaum on recent calls

“Good afternoon, and welcome to Travere Therapeutics third quarter 2023 financial results and corporate update call. Thank you all for joining. Today's call will be led by our Chief Executive Officer, Dr. Eric Dube.”
Head of Investor Relations, Travere Therapeutics, Inc. Q3 FY2023 Earnings Call ·
“Good afternoon, and welcome to Travere Therapeutics second quarter 2023 financial results and corporate update call. Thank you all for joining us. Today's call will be led by our Chief Executive Officer, Dr. Eric Dube.”
Head of Investor Relations, Travere Therapeutics, Inc. Q2 FY2023 Earnings Call ·
“And welcome to Travere Therapeutics first quarter 2023 financial results and corporate update call. Today's call will be led by our Chief Executive Officer, Dr. Eric Dube.”
Head of Investor Relations, Travere Therapeutics, Inc. Q1 FY2023 Earnings Call ·
“Good afternoon, and welcome to Travere Therapeutics' Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. Thank you all for joining us.”
Head of Investor Relations, Travere Therapeutics, Inc. Q4 FY2022 Earnings Call ·

Affiliation history

Company network

Leadership on record at Travere Therapeutics, Inc.

Recent activity